SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Mutation V18M

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

There is one clinical trial.

Clinical Trials


1 The Use of an Open Label Placebo to Treat Cancer Related Fatigue in Cancer Survivors

The purpose of this randomized-controlled, crossover pilot trial is to evaluate the feasibility, acceptability and effects of a non-deceptive (open-label) administration of placebo pills for treating cancer related fatigue (CRF). If significant effects are found, the investigators will later determine if the presence of a COMT Val18Met genotype variant predicts placebo responses.

NCT02522988 Fatigue Behavioral: Open-label placebo intervention
MeSH:Fatigue
HPO:Fatigue

If significant effects are found, the investigators will later determine if the presence of a COMT Val18Met genotype variant predicts placebo responses. --- Val18Met ---

Primary Outcomes

Description: Unit of measure: number of enrollees / number of eligible participants as a measure of feasibility.

Measure: Enrollment Rate

Time: End of Study (7 weeks)

Description: Unit of measure: number of accrued participants / recruitment goal (80); odds ration of expected time-to-first participant/ actual time-to-first patient enrollment.

Measure: Accrual Rate as a Measure of Feasibility

Time: End of Study (7 weeks)

Description: Unit of measure: number of placebos taken / number prescribed (84)

Measure: Adherence Rate as a Measure of Feasibility

Time: End of Study (7 weeks)

Description: Unit of measure: number eligible for enrollment / number screened

Measure: Eligibility as a measure of Feasibility

Time: End of Study (7 weeks)

Description: Unit of measure: number retained in study / number enrolled (goal = 75% of enrolled

Measure: Retention as a measure of Acceptability

Time: End of Study (7 weeks)

Secondary Outcomes

Description: Units of measure: units on a scale using the Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF) instrument. 30-questions measure the global, somatic, affective, behavioral and cognitive manifestations of fatigue. Scale for items = 0 (not at all) - 4 (extremely)

Measure: Measure of fatigue manifestation

Time: Baseline, 3 weeks, 4 weeks and 7 weeks

Description: Unit of measure: units on a scale using the Medical Outcomes Study 36-Item Short Form (MOS-36) instrument. The 36-item instrument measures the impact of fatigue on vitality, physical functioning, emotional functioning, social functioning and mental health. Scale for items = 1 (limited a lot) - 3 (Not limited at all)

Measure: Measurement of impact of fatigue on quality of life

Time: Baseline, 3 weeks, 4 weeks and 7 weeks

Description: Unit of measure: units on a scale using the FACT-Fatigue instrument; scale for impact is 0 = not at all; 10 = very much.

Measure: Measurement of the impact of fatigue on physical function

Time: Baseline, 3 weeks, 4 weeks and 7 weeks

Description: Units of measure: units on a scale using the Fatigue Symptom Inventory (FSI) instrument. Scale = 0 (no fatigue / no interference) to 10 (extreme fatigue / interference)

Measure: Measurement of fatigue severity

Time: Baseline, 3 weeks, 4 weeks and 7 weeks

Other Outcomes

Description: Investigators will collect and store saliva samples so, should significant OLPI effects be obtained, we can evaluate whether a potential biomarker (COMT Val158Met variant) associates with placebo responsiveness.

Measure: Test for the presence of a COMT Val158Met/Val or Val/Val variant gene

Time: Baseline


HPO Nodes


HP:0012378: Fatigue
Genes 398
PFN1 SOX3 ATRX VHL LBR BIRC3 BLNK GNAS CD79A SH2B3 STAT5B EPCAM NF1 MEFV IL12A-AS1 CTLA4 MLX PON1 PNPLA8 RPL5 RUNX1 KCNQ1 RRM2B GPR35 ELANE PPARGC1A IGH GLA DBH CCR1 MLH3 XPC MSH2 CCND1 KLRC4 ATP7A KCNQ3 PSTPIP1 PALLD HLA-B TCF4 CDKN2A RUNX1 BCOR ALB AGK GBA NEK1 CFI IRF2BP2 ALAS2 MRAP OPTN MYD88 CAV3 NKX2-1 BCL2 CCDC78 PALB2 C9ORF72 UNC13A DNAJC6 SDHA SMAD4 TBX19 C4A ATM PDE8B RPS28 NUMA1 SCN8A MMACHC NFKB2 PRKAR1A MST1 HBA1 RPL11 SOX3 SLC25A11 SCNN1A ERBB4 UBQLN2 SLC18A3 PODXL HFE SQSTM1 ARMC5 HLA-DPB1 PRRT2 MET NPM1 SLC26A4 NAGS FAS CCNF TSHR STAR SDHD IL12A SPIB PREPL RET POU1F1 WIPF1 DLST LHX4 TSC1 HNF1A TET2 DCTN1 STEAP3 FOXE1 TREM2 NABP1 FGFR1 PYGM HESX1 WAS SLC5A5 INSR NEFH KCNN4 IL23R SOD1 HESX1 ERAP1 RPS27 RPS7 FOXP1 STAT6 CALR CFH DMPK DUOX2 BRCA1 VCP TARDBP GCK DYSF TBL1XR1 CCND1 MSH6 PMS1 COL1A2 ACADM BCR SDHB IGLL1 MEN1 EPOR PRTN3 UNC93B1 MDH2 DNMT3A HLA-B BRCA2 JAK2 HMGCL DDB2 RPS17 CHMP2B CFAP410 IL12RB1 PAX8 LHX4 CPT1A ERCC2 RPL35A MMEL1 RPS20 PRKACA COL5A2 RET RPL31 PYGL RPL15 IRF5 NKX2-5 HLA-DRB1 EPHA4 ABL1 ERCC4 RPL27 DNM1L SLC25A4 SMAD3 POU1F1 HAVCR2 OPA1 PLEC SLC26A4 JAK2 KCNE1 CBL SDHB KIT ATP13A2 RPS24 PGM1 DAO GATA1 NAB2 SDHB SDHAF2 VHL DMD PDGFRA PMS2 ALB ERCC5 SLC11A1 PON2 CPT2 IGHM RPS26 PROP1 PML PIGT AP2S1 SCNN1B HNRNPA1 SLC18A2 PROP1 TSHR POMGNT1 COQ2 RPL26 RPS29 SDHC MALT1 SDHD HESX1 FUS SDHC FH SCN2A GLE1 C1QBP GPR101 LHX3 MATR3 RPS10 CPT2 PON3 CHRND BCL10 BCL6 ZBTB16 AIP GLT8D1 TAZ TGFBR2 KRAS SERPINA6 HLA-B TWNK IKZF1 UBAC2 ABCC2 RARA MORC2 MYH7 ANXA11 POLG EPAS1 CDH23 SLC2A10 PTPN22 TFR2 SEMA4A POLG2 GCH1 PROKR2 KCNQ2 TLR3 TAF15 TRAF3 FIP1L1 ASXL1 CDC73 SOX2 TNPO3 ATXN2 TXNRD2 TRNK HLA-DPA1 LRRC8A MPL TSC2 DUOXA2 TLR4 CTNNB1 PIK3CA NLRP3 FAN1 PIGA IGH TWNK KIT TICAM1 PROP1 RPS15A NR3C1 TPO XPA PRKAR1A BMPR1A ERCC3 TET2 KIF23 TBK1 TSHB MC2R MEN1 ATP13A2 TK2 CDC73 IL10 IL12B TET2 RPL18 STAT4 MMADHC POU2AF1 FIG4 STAT3 ARMC5 VPS13A MPL PRPH TSR2 NNT HNF4A TP53 CDH23 COL5A1 BTNL2 GLI2 PTPN22 PAX8 FOXA2 CHCHD10 PTPN3 TMEM127 CD79B GATA2 IL12A MLH1 TBK1 ADA2 SRSF2 SLC12A3 IGH KRAS ARNT2 IYD TG SLC3A1 PHKG2 SMAD3 PDE11A COL1A1 ANG VAPB SLC40A1 NLRP3 OTX2 NR3C1 RPL35 HELLPAR MAX KIF1B FGF23 TCF3 PIEZO1 PIK3R1 AIP PHKA2 SDHA OTX2 HLA-DRB1 SLC25A26 TNXB CDH23 RPS19 CD46 BTK SLC4A1 SYNJ1 FTL TNFSF15 SCNN1G VHL USP8 TET2 TET2 JAK2 HBA2
Protein Mutations 3
T25W V158M V18M
SNP 0